Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry

[1]  J. Szer,et al.  Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry , 2017, Internal medicine journal.

[2]  S. Brunet,et al.  Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry , 2017, Annals of Hematology.

[3]  J. Szer,et al.  Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. , 2017, Blood cells, molecules & diseases.

[4]  C. Parker.  Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2016, Hematology. American Society of Hematology. Education Program.

[5]  Pierre-Yves Dumas,et al.  Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study , 2016, American journal of hematology.

[6]  Sung-Soo Yoon,et al.  Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry , 2016, Journal of Korean medical science.

[7]  R. Brodsky,et al.  Paroxysmal nocturnal hemoglobinuria. , 2014, Blood.

[8]  A. Hinz,et al.  European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six European general population normative studies , 2014, Acta oncologica.

[9]  J. Maciejewski,et al.  Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2014, Haematologica.

[10]  Vivek R. Sharma.  Paroxysmal nocturnal hemoglobinuria: pathogenesis, testing, and diagnosis. , 2013, Clinical advances in hematology & oncology : H&O.

[11]  P. Hillmen,et al.  Thrombosis in paroxysmal nocturnal hemoglobinuria. , 2013, Blood.

[12]  Sung-Soo Yoon,et al.  Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry , 2013, International Journal of Hematology.

[13]  C. Parker.  Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. , 2011, Hematology. American Society of Hematology. Education Program.

[14]  R. Brodsky,et al.  Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia , 2010, European journal of haematology.

[15]  G. Khursigara,et al.  Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria , 2010, American journal of hematology.

[16]  N. Young,et al.  Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine , 2010, Haematologica.

[17]  F. Craig,et al.  Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry , 2010, Cytometry. Part B, Clinical cytometry.

[18]  M. Gladwin,et al.  Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria , 2010, British journal of haematology.

[19]  N. Young,et al.  The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. , 2009, Seminars in hematology.

[20]  M. Mohty,et al.  Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. , 2008, Blood.

[21]  A. Risitano,et al.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents , 2008, Biologics : targets & therapy.

[22]  Neal Young,et al.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria. , 2005, Blood.

[23]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[24]  E. S. Garrett,et al.  Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays , 2004, British journal of haematology.

[25]  S. Hall,et al.  Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan , 2004, Medicine.

[26]  S. Richards,et al.  Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). , 2003, Blood.

[27]  D. Cella,et al.  Fatigue in cancer patients compared with fatigue in the general United States population , 2002, Cancer.

[28]  D. Swirsky,et al.  Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria. , 1998, Blood.

[29]  D. Cella,et al.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.

[30]  J. Mary,et al.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.

[31]  S M Lewis,et al.  Natural history of paroxysmal nocturnal hemoglobinuria. , 1995, The New England journal of medicine.

[32]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.